Streetbeat News

NONOF

Novo Nordisk

https://www.novonordisk.com/

CEO

Lars Fruergaard Joergensen

Employees

2,020

Industry

Pharmaceutical Preparation Manufacturing

Open

103.00

Mkt cap

466B

Volume

1.7K

High

105.94

P/E Ratio

35.35

52-wk high

149.55

Low

103.00

Div yield

0.01

52-wk low

94.36

Novo Nordisk's obesity medication, Wegovy, has shown greater weight loss in women with heart disease compared to men. The study data was presented at the American Diabetes Association’s scientific meeting. The Centers for Medicare and Medicaid Services (CMS) is reviewing the inclusion of Wegovy in its coverage for heart disease patients with obesity. Goldman Sachs analysts have re-rated Novo Nordisk, expecting significant growth in the weight-loss drug market.

Portfolio Pulse from Benzinga Neuro

June 24, 2024 | 7:17 am

Zealand Pharma announced positive Phase 1b trial results for its weight management drug, petrelintide, showing significant weight loss and good tolerability. This news comes as the weight-loss drug market, dominated by Novo Nordisk's Ozempic and WeGovy, is projected to grow significantly.

Portfolio Pulse from Benzinga Neuro

June 21, 2024 | 12:12 pm

New side effects of the weight loss drug Ozempic, manufactured by Novo Nordisk Inc. (OTC:NONOF), are causing concern among patients and healthcare professionals. The drug is under scrutiny for potential long-term side effects such as constant nausea, abdominal pain, and severe stomach conditions. The drug could also increase the risk of inflammatory diseases like pancreatitis and certain types of bowel obstruction. Experts recommend personalized dosage management and urge patients to report any adverse side effects to the manufacturers or the FDA.

Portfolio Pulse from Benzinga Neuro

October 09, 2023 | 9:43 am

The family of a man who committed suicide is seeking a warning label on the weight loss drug Ozempic, claiming it contributed to his death. The man's mood changes were linked to his use of the Type 2 diabetes medicine. The FDA and the drug’s manufacturer, Novo Nordisk (OTC:NONOF), are monitoring the safety of the drug and will take appropriate actions if a new safety signal for suicidal ideation/behavior is identified.

Portfolio Pulse from Benzinga Neuro

September 11, 2023 | 8:40 am

Novo Nordisk's diabetes and weight loss drug, Ozempic, may have potential to help break addictions, according to The Guardian. Users have reported a decrease in addictive behaviors, such as smoking and drinking, while on the medication. Early studies have shown that semaglutide, the scientific name for Ozempic, seems to reduce binge drinking in rodents, and previous generations of GLP-1 drugs have been associated with reduced consumption of nicotine, cocaine, and opioids. Clinical trials are underway to determine whether semaglutide can help smokers and people with alcohol use disorder reduce their intake.

Portfolio Pulse from Benzinga Newsbot

July 03, 2023 | 7:26 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.